 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DURECT: Reading Into AHFIRM Mortality Rates...

DURECT: Reading Into AHFIRM Mortality Rates

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update PR Newswire CUPERTINO, Calif...

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

Durect Earnings Preview

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update PR...

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

In trading on Wednesday, drugs shares were relative laggards, down on the day by about 2.8%. Helping drag down the group were shares of Durect, down about 76.2% and shares of Maravai LifeSciences...

Video: Wednesday Sector Laggards: Drugs, Television & Radio Stocks

DURECT Corporation (NASDAQ: DRRX) released topline

read more...

Why Is Pain & Liver Disease Focused DURECT Stock Plunging Today?

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Durect falls 71% to 75c after Phase 2B study misses primary endpint

Durect trading resumes

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality DURECT Corporation Announces Topline...

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM...

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Watchers	8,537
52-Wk Low	$0.4703
52-Wk High	$9.50

Market Cap	$18.49M
Volume (M)	257,268.00
52-Wk High	$9.50
52-Wk Low	$0.4703

DRRX Durect Corp

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community